Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology. Claims data gathered between 2000 and 2004 showed that while oral drugs approved in 2000 cost around $1,869 per month, those approved in 2014 cost an average of $11,325.
Read the full article here.